A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation

Gut

Volumn 62, Issue 5, 2013, Pages 708-715

  Bharucha, Adil E ^a,b   Low, Phillip ^b   Camilleri, Michael ^a   Veil, Erica ^a   Burton, Duane ^a   Kudva, Yogish ^b   Shah, Pankaj ^b   Gehrking, Tonette ^b   Zinsmeister, Alan R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO; PYRIDOSTIGMINE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BODY MASS; BRADYCARDIA; CELLULITIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TRACT SCINTISCANNING; GASTROINTESTINAL TRANSIT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FUNCTION; MALE; MAXIMUM TOLERATED DOSE; MUSCLE TWITCH; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SEX DIFFERENCE; SIDE EFFECT; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE COLOR;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALGORITHMS; CHOLINESTERASE INHIBITORS; CONSTIPATION; DEFECATION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PYRIDOSTIGMINE BROMIDE; TREATMENT OUTCOME;

EID: 84875866984     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302483     Document Type: Article

References (49)

1. Janatuinen E, Pikkarainen P, Laakso M, et al. Gastrointestinal symptoms in middleaged diabetic patients. Scand J Gastroenterol 1993;28:427-32. (Pubitemid 23116595)
2. Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808-16.
3. Bytzer P, Talley NJ, Hammer J, et al. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 2002;97:604-11. (Pubitemid 34245887)
4. Hasler WL, Coleski R, Chey WD, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol 2008;294:G1384-91.
5. Buysschaert M, Donckier J, Dive A, et al. Gastric acid and pancreatic polypeptide responses to sham feeding are impaired in diabetic subjects with autonomic neuropathy. Diabetes 1985;34:1181-5. (Pubitemid 16218524)
6. Caruana BJ, Wald A, Hinds JP, et al. Anorectal sensory and motor function in neurogenic fecal incontinence. Comparison between multiple sclerosis and diabetes mellitus. Gastroenterology 1991;100:465-70.
7. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut 2010;59:1716-26.
8. Law NM, Bharucha AE, Undale AS, et al. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G1228-37.
9. Battle WM, Snape WJ Jr., Alavi A, et al. Colonic dysfunction in diabetes mellitus. Gastroenterology 1980;79:1217-21. (Pubitemid 11250463)
10. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999;341:137-41. (Pubitemid 29325740)
11. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. JAMA 1983;249:1148.
12. Pasha SF, Lunsford TN, Lennon VA. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology 2006;131:1592-6. (Pubitemid 44708932)
13. Bharucha AE, Low PA, Camilleri M, et al. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008;18:194-202.
14. Osinski MA, Bass P. Chronic denervation of rat jejunum results in cholinergic supersensitivity due to reduction of cholinesterase activity. J Pharmacol Exp Ther 1993;266:1684-90. (Pubitemid 24175822)
15. Inoue T, Okasora T, Okamoto E. Effect on muscarinic acetylcholine receptors after experimental neuronal ablation in rat colon. Am J Physiol 1995;269:G940-4.
16. Leelakusolvong S, Bharucha AE, Sarr MG, et al. Effect of extrinsic denervation on muscarinic neurotransmission in the canine ileocolonic region. Neurogastroenterol Motil 2003;15:173-86. (Pubitemid 36532555)
17. Trojan DA, Collet JP, Shapiro S, et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 1999;53:1225-33. (Pubitemid 29480080)
18. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45:1143-7.
19. Bharucha AE, Wald AM. Anorectal disorders. Am J Gastroenterol 2010;105:786-94.
20. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-8. (Pubitemid 351508480)
21. Cremonini F, Mullan BP, Camilleri M, et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002;16:1781-90.
22. Bharucha AE, Ravi K, Zinsmeister AR. Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol 2010;299:G215-19.
23. Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010;22:415-23, -95.
24. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8. (Pubitemid 30140843)
25. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipationpredominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904. (Pubitemid 39335796)
26. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8. (Pubitemid 47374145)
27. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4. (Pubitemid 27382038)
28. Low PA. Autonomic nervous system function. J Clin Neurophysiol 1993;10:14-27. (Pubitemid 23057967)
29. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc 1993;68:748-52. (Pubitemid 23222298)
30. Low PA, Denq JC, Opfer-Gehrking TL, et al. Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle Nerve 1997;20:1561-8. (Pubitemid 27512345)
31. Maleki D, Camilleri M, Burton DD, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci 1998;43:2373-8. (Pubitemid 28531306)
32. Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: getting the balance right. Gut 2010;59:1288-96.
33. Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011;23:944e-400.
34. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54. (Pubitemid 351749158)
35. Bharucha AE, Camilleri M, Low PA, et al. Autonomic dysfunction in gastrointestinal motility disorders. Gut 1993;34:397-401. (Pubitemid 23080269)
36. Jung H-K, Kim D-Y, Moon I-H, et al. Colonic transit time in diabetic patientsdcomparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med J 2003;44:265-72. (Pubitemid 36592188)
37. He CL, Soffer EE, Ferris CD, et al. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001;121:427-34. (Pubitemid 32729390)
38. Nakahara M, Isozaki K, Hirota S, et al. Deficiency of KIT-positive cells in the colon of patients with diabetes mellitus. J Gastroenterol Hepatol 2002;17:666-70. (Pubitemid 34748157)
39. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:772-81.
40. Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010;22:293e-82.
41. Di Stefano M, Vos R, Klersy C, et al. Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Am J Gastroenterol 2006;101:2797-804. (Pubitemid 44902653)
42. Beckett EAH, Horiguchi K, Khoyi M, et al. Loss of enteric motor neurotransmission in the gastric fundus of Sl/Sl(d) mice. J Physiol 2002;543:871-87.
43. Nagahama K, Matsunaga Y, Kawachi M, et al. Acotiamide, a new orally active acetylcholinesterase inhibitor, stimulated gastrointestinal motor activity in conscious dogs. Neurogastroenterol Motil 2012 In press.
44. Maleki D, Camilleri M, Zinsmeister AR, et al. Effect of acute hyperglycemia on colorectal motor and sensory function in humans. Am J Physiol 1997;273: G859-64.
45. Sims MA, Hasler WL, Chey WD, et al. Hyperglycemia inhibits mechanoreceptormediated gastrocolonic responses and colonic peristaltic reflexes in healthy humans. Gastroenterology 1995;108:350-9.
46. Singer W, Opfer-Gehrking TL, McPhee BR, et al. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2003;74:1294-8.
47. Daube J MrF, ed. Clinical Neurophysiology of Disorders of Muscle and Neuromuscular Junction, Including Fatigue. Amsterdam: Elsevier, 2003.
48. Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37:300-7. (Pubitemid 351304789)
49. Golomb BA. Acetylcholinesterase inhibitors and Gulf War illnesses. Proc Natl Acad Sci U S A 2008;105:4295-300. (Pubitemid 351754374)